With CiPA, human iPSC - cardiomyocytes are employed to assess drug effects on the cardiac action potential to confirm the outcome of in
silico modeling efforts, relying on hiPSC - cardiomyocytes to provide the integrated drug response from multiple native human currents in a human - derived cellular preparation.